Core Viewpoint - The approval of the inactivated vaccine for swine encephalitis by Jinhe Biotechnology's subsidiaries marks a significant advancement in the company's product offerings and enhances its position in the animal vaccine industry [1][2]. Group 1: Vaccine Development - Jinhe Biotechnology announced the approval of a new veterinary drug registration certificate for an inactivated vaccine against swine encephalitis, developed in collaboration with its subsidiaries and Beijing Huikang Yisheng Technology Co., Ltd [1]. - The inactivated vaccine is based on the A6-C strain isolated from infected pigs, providing better antigen matching and immunogenicity, and offering strong immune protection against currently circulating genotype I and III viruses [1]. Group 2: Industry Impact - The approval of the new vaccine is a result of the company's ongoing commitment to research and innovation, which will enhance its ability to provide comprehensive solutions to livestock customers [2]. - This development is expected to strengthen the company's market competitiveness and contribute positively to its sustainable development and research capabilities in the animal vaccine sector [2].

Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].

Group 1 - The company has changed its sponsor institution to Ping An Securities for the 2025 private placement of shares, with the original sponsor, Dongfang Securities, transferring its ongoing supervision responsibilities [2] - The company has signed a tripartite supervision agreement with China Minsheng Bank and Ping An Securities to regulate the management and use of raised funds, ensuring the protection of minority investors' rights [2][3] - The total amount raised from the private placement was approximately RMB 820 million, with a net amount of approximately RMB 802 million after deducting issuance costs [2] Group 2 - The tripartite supervision agreement stipulates that the raised funds will be stored in a dedicated account solely for specific projects, including production process efficiency improvements and energy-saving upgrades [3][4] - Ping An Securities will supervise the use of the raised funds and conduct semi-annual inspections of the fund's storage and usage [4][5] - The agreement includes provisions for notification of large withdrawals and compliance with anti-money laundering regulations [5][6] Group 3 - The company has received a new veterinary drug registration certificate for a new inactivated vaccine for swine encephalitis, developed in collaboration with several subsidiaries and partners [14] - The new vaccine is classified as a Class III veterinary drug and is designed to prevent swine encephalitis, with a recommended dosage of 2ml per pig [15][16] - The approval of this new vaccine is expected to enhance the company's product pipeline and strengthen its market position in the animal vaccine sector [20]

Core Viewpoint - The company has announced a change in its continuous supervision and sponsorship institution, appointing Ping An Securities as the new sponsor for its 2025 stock issuance, while the previous sponsor, Dongfang Securities, will transfer its ongoing supervisory responsibilities to Ping An Securities [2]. Group 1 - The company disclosed the change in sponsorship on December 26, 2025, indicating a strategic shift in its financial oversight [2]. - The new sponsorship arrangement is part of the company's plan to issue stocks to specific investors through a simplified procedure for the year 2025 [2]. - To ensure proper management and use of raised funds and to protect the rights of minority investors, the company has signed a tripartite supervision agreement with China Minsheng Bank and Ping An Securities [2]. Group 2 - The company and its subsidiary, Jinhai Youben Biological Products Co., Ltd., have also entered into a quadripartite supervision agreement with China Merchants Bank and Ping An Securities [2].

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

Core Viewpoint - Jinhe Biology (002688.SZ) announced the approval of a new veterinary drug, an inactivated vaccine for porcine encephalitis (A6-C strain), developed in collaboration with its subsidiaries and Beijing Huikang Yisheng Technology Co., Ltd. [1] Group 1 - The new veterinary drug was approved by the Ministry of Agriculture and Rural Affairs after review [1] - The vaccine is developed by Jinhe Biology's subsidiaries: Hangzhou Youben Animal Vaccine Co., Ltd., Jinhe Youben Biological Products Co., Ltd., and Hohhot Youben Vaccine Technology Co., Ltd. [1] - The approval includes the issuance of a "New Veterinary Drug Registration Certificate" [1]

金河生物科技股份有限公司 关于子公司获得新兽药注册证书的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查， 批准金河生物科技股份有限公司（以下简称"公司"）子公司杭州佑本动物疫苗 有限公司（以下简称"杭州佑本"）、子公司金河佑本生物制品有限公司（以下 简称"金河佑本"）、子公司呼和浩特佑本疫苗科技有限公司（以下简称"呼市 佑本"）与北京汇康益生科技有限公司联合开发的猪乙型脑炎灭活疫苗（A6-C 株）为新兽药，核发了《新兽药注册证书》。详情如下： 一、新兽药产品基本情况 新兽药名称：猪乙型脑炎灭活疫苗（A6-C 株） 证券代码：002688 证券简称：金河生物 公告编号：2026-002 类别：三类 新兽药注册证书号：（2026）新兽药证字 11 号 贮藏与有效期：2～8℃保存，有效期为 18 个月。 二、新兽药产品研发情况和相关市场背景情况 乙型脑炎是一种由病毒引起的人畜共患传染病，猪是其重要宿主和传染源。 目前我国猪场主要使用活疫苗（SA14-14-2 株）进行免疫，长期使用存 ...

证券代码：002688 证券简称：金河生物 公告编号：2026-001 金河生物科技股份有限公司 关于变更保荐机构后重新签订募集资金监管协议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日披 露了《关于变更持续督导保荐机构及保荐代表人的公告》。因公司聘请平安证券 股份有限公司（以下简称"平安证券"）担任公司 2025 年度以简易程序向特定 对象发行股票的保荐机构，原保荐机构东方证券股份有限公司（以下简称"东方 证券"）对公司 2021 年度非公开发行股票并上市尚未完成的持续督导工作由平 安证券承接。鉴于公司保荐机构已变更，为规范募集资金管理和使用，保护中小 投资者的权益，根据《上市公司募集资金监管规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规和规范性文 件及公司《募集资金管理办法》的相关规定，近日，公司与中国民生银行股份有 限公司呼和浩特分行、平安证券共同签订《募集资金三方监管协议》；公司及控 股子公司金河佑本生 ...

Core Viewpoint - The animal health sector experienced a 0.99% increase on January 8, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4082.98, down 0.07%, and the Shenzhen Component Index closed at 13959.48, down 0.51% [1]. - The animal health sector stocks showed varied performance, with BioShares leading the gains at 3.10% [1]. Group 2: Stock Performance - Key stocks in the animal health sector included: - BioShares (600201) closed at 16.61 with a 3.10% increase and a trading volume of 517,400 shares, totaling 853 million yuan [1]. - Huisheng Biological (300871) closed at 22.46, up 2.23%, with a trading volume of 86,000 shares, totaling 193 million yuan [1]. - Dayu Biological (920970) closed at 8.02, up 2.17%, with a trading volume of 19,900 shares, totaling 15.81 million yuan [1]. - Other notable stocks included PlaiKe (603566) and Shunlian Biological (688098), with increases of 1.90% and 1.71% respectively [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 10.1262 million yuan from institutional investors, while retail investors contributed a net inflow of 37.4241 million yuan [2]. - Notably, the main funds showed a net outflow of 47.5503 million yuan from speculative funds [2]. Group 4: Detailed Capital Flow by Stock - BioShares (600201) had a net inflow of 40.3094 million yuan from main funds, while it experienced a net outflow of 8.4352 million yuan from speculative funds [3]. - Gold River Biological (002688) saw a net inflow of 13.2219 million yuan from main funds, with a net outflow of 3.8181 million yuan from speculative funds [3]. - ST Green Health (002868) had a net inflow of 9.7760 million yuan from main funds, but a significant net outflow of 20.7609 million yuan from speculative funds [3].

Group 1 - The company has successfully established a production capacity of 3,000 tons of astaxanthin per year [1] - The related product, red yeast rice as a feed additive, has received the necessary product approval number and is currently in the market promotion phase [1] - The company is expected to provide further details on the operational situation in future announcements [1]